TG Therapeutics (NASDAQ:TGTX) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS

TG Therapeutics (NASDAQ:TGTX) announced its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.02), Briefing.com reports. TG Therapeutics had a return on equity of 12.89% and a net margin of 5.42%. The business had revenue of $63.47 million during the quarter, compared to analysts’ expectations of $54.60 million. During the same period in the previous year, the company posted ($0.28) EPS. TG Therapeutics’s revenue for the quarter was up 713.5% on a year-over-year basis.

TG Therapeutics Stock Performance

Shares of NASDAQ:TGTX traded up $0.12 during midday trading on Thursday, reaching $16.00. The company’s stock had a trading volume of 4,014,531 shares, compared to its average volume of 4,279,764. The firm has a market capitalization of $2.47 billion, a PE ratio of 800.40 and a beta of 2.33. TG Therapeutics has a twelve month low of $6.46 and a twelve month high of $35.67. The stock has a fifty day moving average of $15.13 and a 200 day moving average of $14.33. The company has a quick ratio of 5.18, a current ratio of 5.92 and a debt-to-equity ratio of 0.62.

Insider Transactions at TG Therapeutics

In other news, Director Laurence N. Charney sold 22,000 shares of the stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total value of $351,340.00. Following the sale, the director now owns 215,229 shares in the company, valued at $3,437,207.13. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 9.20% of the company’s stock.

Wall Street Analyst Weigh In

TGTX has been the subject of a number of analyst reports. The Goldman Sachs Group increased their target price on shares of TG Therapeutics from $12.00 to $13.00 and gave the company a “neutral” rating in a research report on Thursday, February 29th. StockNews.com cut shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 24th. HC Wainwright reissued a “buy” rating and set a $45.00 target price on shares of TG Therapeutics in a research report on Thursday, April 18th. B. Riley upped their price target on shares of TG Therapeutics from $24.00 to $29.00 and gave the company a “buy” rating in a research note on Monday, February 5th. Finally, LADENBURG THALM/SH SH upped their price target on shares of TG Therapeutics from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $29.17.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.